CHARLES T. RICHARDSON, M.D.
This content is PDF only. Please click on the PDF icon to access.
Sucralfate has been approved by the Food and Drug Administration for use in treating patients with active duodenal ulcers. Although sucralfate is new in the United States, it has been used for several years in Japan. Sucralfate neither reduces acid secretion nor neutralizes acid. Instead, it is believed to act primarily at the ulcer crater, forming a protective coat that shields the lesion from pepsin and, perhaps, acid (1-3).
Sucralfate is the salt of sucrose octasulfate- and [A12(OH)5]+. When the drug reaches the acidic environment (pH, < 3 to 4) of the stomach, some [A12(OH)5] + ions dissociate from sucrose
RICHARDSON CT. Sucralfate. Ann Intern Med. 1982;97:269–272. doi: https://doi.org/10.7326/0003-4819-97-2-269
Download citation file:
Published: Ann Intern Med. 1982;97(2):269-272.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use